- Home
- NRDS vs OCS Comparison
NRDS vs OCS Comparison
Compare NRDS & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRDS | OCS |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Switzerland |
| Employees | 650 | 60 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 629.0M | 715.8M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NRDS | OCS |
|---|---|---|
| Price | $9.83 | $12.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $15.00 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 693.4K | 271.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.42 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $836,600,000.00 | N/A |
| Revenue This Year | $10.13 | $466.06 |
| Revenue Next Year | $7.11 | $479.73 |
| P/E Ratio | $27.03 | ★ N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $7.33 | $10.52 |
| 52 Week High | $16.24 | $34.48 |
Technical Indicators
Market Signals| Indicator | NRDS | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 54.69 |
| Support Level | $9.36 | $10.63 |
| Resistance Level | $11.05 | $13.28 |
| Average True Range (ATR) | 0.40 | 0.57 |
| MACD | 0.07 | 0.29 |
| Stochastic Oscillator | 76.43 | 85.49 |
Price Performance
Historical ComparisonAbout NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.